Oral Antiviral Market Thumbnail Image

2023

Oral Antiviral Market

Oral Antiviral Market Size, Share, Competitive Landscape and Trend Analysis Report, by Indication, by Drug class, by Distribution channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

LS : Pharmaceuticals

Select an option
Author's: Shraddha Mali | Roshan Deshmukh
Publish Date:

Get Sample to Email

Oral Antiviral Market Research, 2031

The global oral antiviral market size was valued at $35,213.48 million in 2021, and is projected to reach $43,394.00 million by 2031, growing at a CAGR of 2.1% from 2022 to 2031. from 2022 to 2031. Oral antiviral drugs are medications that are taken by mouth to treat viral infections. Antiviral drugs exhibit their action by inhibiting their replication, entry into host cells, or release from infected cells. Antiviral drugs are used to treat a variety of viral infections, such as influenza, herpes simplex virus, hepatitis B and C, HIV, and others. In addition, these drugs are used to prevent or treat infections, depending on the specific situation. Some antiviral drugs are also used as a prophylactic measure to prevent infections, such as in the case of people who are at high risk of contracting HIV. The effectiveness of oral antiviral drugs depends on the specific type of virus, the stage of the infection, and the individual’s immune system. Moreover, antiviral drugs reduce the duration and severity of symptoms, while others prevent the virus from multiplying and spreading throughout the body.

Oral Antiviral Market

Market dynamics

Growth & innovations in the pharmaceutical industry for the manufacturing of oral antiviral drugs creates an opportunity for the oral antiviral market. Rise in product approvals of various oral antiviral agents, increase in number of clinical trials of new drugs by various key players across the globe are set to affect the market growth positively. In addition, rising prevalence of viral infections such as hepatitis, influenza, is driving demand for effective oral antiviral drugs thus driving the growth of the market. The growth of the oral antiviral market is expected to be driven by emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of human immunodeficiency virus (HIV) cases in adults, and surge in demand for oral antiviral drugs for management of viral infection. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.

Various organizations along with the government are counselling people regarding viral infections such as hepatitis and influenza. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. Various animations through health apps to educate people regarding HIV infection and usage of medications have contributed toward the growth of oral antiviral market. The demand for effective oral antiviral agents is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Moreover, an increase in promotional activities by manufacturers and growth in awareness for proper treatment of viral infection in the general population is expected to fuel their adoption in the near future.

However, side effects of the oral antiviral drugs used to treat viral infections restrain the growth of the oral antiviral market. In addition, the absence of favorable reimbursement policies is expected to constrain the growth of the market. In contrast, rise in demand for novel oral medications, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for viral infections offers lucrative opportunities to key players of the oral antiviral market. 

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The COIVID-19 pandemic positively impacted the growth of the oral antiviral market, owing to the rise in number of patients suffering from viral infections. The pandemic increased patient attendance at outpatient medical visits, including preventive services such as screening of patients for various viral diseases such HIV, influenza, and other viral infections. The COVID-19 pandemic led to a sharp increase in demand for oral antiviral drugs as people look for ways to protect themselves from the virus. In addition, due to the sudden surge in demand, there have been shortages of some oral antiviral drugs, leading to price hikes and difficulties in accessing these drugs. Thus, pandemic positively impacted the growth of the oral antiviral market. Further, a rise in regulatory approvals and favorable policies for development of novel therapeutics to treat viral infections is anticipated to provide lucrative oral antiviral market opportunity to key market players. 

Segmental Overview

The oral antiviral market is segmented into indication, drug class, distribution channel and region. On the basis of indication, the market is categorized into human immunodeficiency virus (HIV), hepatitis, influenza and others. On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

By Indication  

The market is categorized into human immunodeficiency virus (HIV), hepatitis, influenza, and others. The human immunodeficiency virus (HIV) segment accounted for the oral antiviral market share in 2021 and is expected to witness highest CAGR during the forecast period, owing to rise in prevalence of HIV cases across the globe and rise in number of key players offering novel medications.

Oral Antiviral Market
By Indication
Your browser does not support the canvas element.

Human Immunodeficiency Virus (HIV) segment dominated the market in 2021 and the hepatitis segment is expected to be lucrative during the forecast period

By Drug Class 

The market is categorized into protease inhibitors, reverse transcriptase inhibitors, and others. The reverse transcriptase inhibitors segment accounted for oral antiviral market size in 2021 and is expected to witness highest CAGR during the forecast period owing to increase in use of these drugs for treating HIV and hepatitis as these drugs are highly effective and used in combination with other oral antivirals for treating viral infections.

Oral Antiviral Market
By Drug Class
Your browser does not support the canvas element.

Reverse transcriptase inhibitors segment dominated the market in 2021 and others segment is expected to be lucrative during the forecast period


  
By Distribution Channel 

The market is categorized into hospital pharmacies, drug stores and retail pharmacies and online providers. The drug stores and retail pharmacies segment occupied largest share in 2021 and is expected to remain dominant during forecast period owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period.  The online providers segment is projected to register the highest CAGR during the forecast period owing to the rise in popularity of online pharmacies and the number of users preferring online pharmacies.

Oral Antiviral Market
By Distribution Channel
Your browser does not support the canvas element.

Drug store and retail pharmacies segment dominated the market in 2021 and online providers segment is expected to be lucrative during the forecast period


 

By Region

The oral antiviral market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for largest share in 2021 and is expected to remain dominant during the forecast period owing to rise in prevalence of viral infections such as human immunodeficiency virus (HIV) & hepatitis C, presence of key players offering oral antivirals and rise in healthcare infrastructure drive the growth of oral antiviral market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of oral antiviral agents, increase in viral infection cases and number of pipeline medications for treating viral infections, thereby driving the oral antiviral market growth during the forecast period. 

Oral Antiviral Market
By Region
2031
North America 
Europe
Asia-Pacific
LAMEA

North America dominated the market in 2021 and Asia-Pacific is expected to be lucrative during the forecast period

Presence of several major players, such as Gilead Sciences, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd and advancement in manufacturing technology for development of effective medications for viral infections in the region is expected to drive the growth of oral antiviral market. In addition, various private organizations organize educating camps for awareness of viral infections and treatment options available across the globe, thereby driving growth of this market. Furthermore, the presence of well-established healthcare infrastructure, and the rise in adoption rate of new medications for treating viral infections are expected to drive the market growth. Furthermore, various product approval and contract agreements as key strategies adopted by the key players in this region further boost the oral antiviral market forecast. 

Asia-Pacific is expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to the presence of key players in the region. Moreover, the rise in adoption of various new medications such as Xofluza (baloxavir marboxil) for influenza is expected to drive the growth of the market. In China, rise in prevalence of viral infections such as HIV resulting in demand of oral antiviral drugs, thus driving the growth of market. For instance, according to UNAIDS 2022, 1,250,000 people are suffering from HIV infection, thus rise in prevalence of viral infections is anticipated to drive the market growth. Further, many countries such as Australia, awareness programs are being organized every year to educate people about viral infections and available treatment options. Thus, such awareness campaigns are expected to propel market expansion. Asia-Pacific offers profitable opportunities for key players operating in the oral antiviral market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising in spending for viral infections, as well as well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region. 

Competition Analysis

Competitive analysis and profiles of the major players in the oral antiviral market, such as AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc., are provided in this report. Major players have adopted product approval, funding, and agreement as key developmental strategies to improve the product portfolio of the oral antiviral industry. 

Some Examples of Product Approval in the Market 

  • In January 2023, Roche announced that the European Commission (EC) has approved Xofluza (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza.
  • In September 2019, AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6).


Some Examples of Agreement in the Market 

  • In March 2021, Gilead Sciences, Inc., and Merck announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antiviral market analysis from 2021 to 2031 to identify the prevailing oral antiviral market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the oral antiviral market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global oral antiviral market trends, key players, market segments, application areas, and market growth strategies.

Oral Antiviral Market Report Highlights

Aspects Details
icon_1
Market Size By 2031

USD 43.4 billion

icon_2
Growth Rate

CAGR of 2.1%

icon_3
Forecast period

2021 - 2031

icon_4
Report Pages

385

icon_5
By Indication
  • Hepatitis
  • Human Immunodeficiency Virus (HIV)
  • Influenza
  • Others
icon_6
By Drug class
  • Protease inhibitors
  • Reverse transcriptase inhibitors
  • Others
icon_7
By Distribution channel
  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

Viatris Inc., Merck & Co., Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Gilead Sciences, Inc., Johnson & Johnson, Bristol-Myers Squibb Company

Analyst Review

This section provides various opinions of top-level CXOs in the global oral antiviral market. According to the insights of CXOs, increase in demand for novel oral antivirals and rise in investments for oral antivirals globally is expected to offer profitable opportunities for the expansion of the market. In addition, favorable government initiatives and higher spending for oral antivirals have piqued the interest of several companies to develop oral antivirals.  

CXOs further added that increase in adoption of oral antivirals for human immunodeficiency virus (HIV) is expected to boost the growth of market. In addition, the increasing burden of viral infections across the globe has resulted in a rise in demand of novel therapeutics, thus driving the growth of the market. Further, geriatric people are prone to various viral infections, thus a rise in the number of geriatric population results in rise in demand of effective oral medications, thereby driving the growth of market. 

Furthermore, North America accounted for largest share in 2021 and is expected to remain dominant during the forecast period owing to rise in prevalence of viral infections such as hepatitis C, presence of key players offering oral antivirals and rise in healthcare infrastructure drive the growth of oral antiviral market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of oral antiviral agents, increase in viral infection cases and number of pipeline medications for treating viral infections, thereby driving the growth of market during the forecast period.

Author Name(s) : Shraddha Mali | Roshan Deshmukh
Frequently Asked Questions?

Rise in demand of novel therapeutics for treating viral infections and rise in regulatory approvals are the upcoming trends of oral antiviral market.

Human Immunodeficiency Virus (HIV) is the leading indication of oral antiviral.

North America is the largest regional market for oral antiviral.

The oral antiviral market was valued at $35,213.48 million in 2021 and is projected to reach $43,394.00 million by 2031, registering a CAGR of 2.1% from 2022 to 2031.

Major Key players that operate in the global oral antiviral market are AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

2021 is the base year of the oral antiviral market.

2022 to 2031 is the forecast year of the oral antiviral market.

Loading Table Of Content...

Loading Research Methodology...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Oral Antiviral Market

Global Opportunity Analysis and Industry Forecast, 2022-2031